Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients in final stage of start-up preparations
“We are very optimistic about the prospects of our investigational drug Multikine in 2025 and 2026. We look ahead to Multikine being able to deliver much needed relief to a patient population with a severe unmet medical need. We see several very important milestones and value drivers upcoming. Positive data on presurgical response rates, previously shown to be indicative of overall survival, could enable us to apply for early approval,” stated CEL-SCI CEO, Geert Kersten. “This confirmatory Registration Study is designed to do two things: create a new standard of care for newly diagnosed treatment naïve locally advanced head and neck cancer patients; and provide survival benefit for the population of patients with low/negative tumor expression of PD-L1, those patients who have historically not responded well to widely used checkpoint inhibitors such as Keytruda and Opdivo.”
Share:
More News
PharmaMar has submitted a Marketing Authorization Application to the European Medicines Agency for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer, whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. The MAA submission
“At SR One, our mission is to invest in companies that we believe have the ability to innovate and advance transformational new therapies in areas of high unmet medical need,” said Simeon George, M.D., Chief Executive Officer and Managing Partner at SR One. “Fore Bio is focused on resetting the
The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of TACE-progression-free survival (TACE PFS*), and the other primary endpoint of overall survival (OS) is immature at the prespecified first interim analysis. Meanwhile, a clinically meaningful PFS by RECIST v1.1** was also observed. Detailed findings from
“The positive CHMP recommendation for the Itovebi-based regimen represents a significant step towards providing people in the EU with PIK3CA-mutated, ER-positive advanced breast cancer with a targeted therapy in the first-line setting,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This recommendation is
